Sugi Predict

Sugi Predict / Compounds / SCHEMBL25810669

SCHEMBL25810669

SCHEMBL25810669

CC(C)(C)OC(=O)N1CC2(CCN(c3ccc4cc(C(=O)O)sc4c3)CC2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCD5 Q86SK9 1/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ NR1H4 Q96RI1 2/20 0.42
▸ ACKR3 P25106 1/20 0.41
▸ ACACB O00763 3/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ GPR183 P32249 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ HDAC2 Q92769 2/20 0.39
▸ CHRNA7 P36544 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25810786 0.91 ACKR3 (0.41) SCD5CYP11B2NR1H4ACKR3CYP2C9
SCHEMBL30492870 0.91 ACKR3 (0.41) SCD5CYP11B2NR1H4ACKR3CYP2C9
SCHEMBL25810667 0.89 ACKR3 (0.41) SCD5CYP11B2ACKR3ACACBCYP2C9
SCHEMBL25252167 0.87 MAPT (0.53) ACKR3CYP2C9ALDH1A1LMNAMAPT
SCHEMBL30492816 0.87 MAPT (0.53) ACKR3CYP2C9ALDH1A1LMNAMAPT
SCHEMBL30492841 0.79 ACKR3 (0.40) ACKR3CYP2C9ALDH1A1LMNAMAPT
SCHEMBL31025966 0.79 ACKR3 (0.40) ACKR3CYP2C9ALDH1A1LMNAMAPT
SCHEMBL30492865 0.79 CHRNA7 (0.47) NR1H4HDAC2CHRNA7HDAC1
SCHEMBL25810429 0.79 CHRNA7 (0.47) NR1H4HDAC2CHRNA7HDAC1
SCHEMBL25301143 0.78 CHRNA7 (0.47) NR1H4HDAC2CHRNA7HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) 2025-03-06 — — US disclosed
WO-2025002040-A1 CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海京新生物医药有限公司 2025-01-02 — — WO disclosed
EP-4458824-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR Shanghai Jingxin Biomedical Co., Ltd. (CN) 2024-11-06 — — EP disclosed
CN-118488951-A Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation 上海京新生物医药有限公司 2024-08-13 — — CN disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 — — WO disclosed
WO-2023125376-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR 上海京新生物医药有限公司 2023-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074902-A1 FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR HTT, PARK7, FUS SCD5 3028/4885CYP11B2 4672/4885NR1H4 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.